FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1946652904> ?p ?o ?g. }

• W1946652904 endingPage "138" @default.
• W1946652904 startingPage "137" @default.
• W1946652904 abstract "We read with interest the article by Li-Wan-Po and colleagues on the functional and clinical implications of the recently discovered CYP2C19*17 variant allele [1]. The authors examine the available literature on the influence of the CYP2C19*17 allele on the disposition of a number of clinically used medicines including voriconazole that are metabolized by this enzyme. The authors conclude that while the CYP2C19*17 allele is associated with increased enzymatic activity, the magnitude of these changes is unlikely to be clinically significant with the possible exception of clopidogrel and tamoxifen [1]. While few studies have assessed the impact of CYP2C19*17 on voriconazole, the available evidence suggests its clinical relevance should not yet be discounted. Voriconazole is indicated as a first line agent in the treatment of invasive pulmonary aspergillosis [2] and is known to be predominantly metabolized by CYP2C19, and to a lesser extent by CYP2C9 and CYP3A4 [3]. Voriconazole displays non-linear pharmacokinetics and high inter-individual variability [4], with CYP2C19 genotype accounting for 49% of the variance observed in apparent oral clearance [5]. Several studies have demonstrated a relationship between voriconazole serum concentrations and clinical efficacy and toxicity [6–8]. Pascual and colleagues prospectively identified that a lack of response to therapy was more common when trough voriconazole concentrations were below 1 mg l−1 (46% treatment failure) than when concentrations exceeded this value (12% treatment failure) [7]. Neurological toxicity due to voriconazole has been associated with concentrations above 5.5 mg l−1[9], highlighting the narrow therapeutic range associated with this antifungal [10]. Wang et al. [11] examined the pharmacokinetics of voriconazole following a single oral dose in CYP2C19*17 heterozygotes (CYP2C19*1/*17) compared with homozygous extensive metabolizers (CYP2C19*1/*1) and poor metabolizers (CYP2C19*2/*2) [11], as discussed in the review by Li-Wan-Po et al.[1]. While the sample size was small, CYP2C19*17 heterozygotes were found to have a significantly lower systemic exposure compared with homozygous extensive metabolizers (mean AUC0–24 3.39 and 6.18 µg h ml−1, respectively) [11]. The 95% confidence intervals for the AUC0–24 of voriconazole in people with these two genotypes do not overlap (Figure 1). Significant differences were also found between people carrying different genotypes in voriconazole half-life and clearance [11]. A later pharmacokinetic study by Weiss et al. also found that subjects carrying the CYP2C19*17 allele had a lower peak and total voriconazole exposure compared with homozygous extensive metabolizers (CYP2C19*1/*1) [5], although the magnitude of the differences were smaller than those found by Wang et al. [11]. Mean AUC0–24 and 95% confidence intervals for CYP2C19*1/*17 heterozygotes (n= 4) and CYP2C19*1/*1 homozygotes (n= 8) from Wang et al. [11] Taken together, these studies demonstrate voriconazole exposure is reduced in subjects carrying a single CYP2C19*17 allele, potentially by up to half compared with homozygous extensive metabolizers [11]. These findings suggest subjects carrying a CYP2C19*17 allele may be at greater risk of sub-therapeutic voriconazole concentrations, and subsequently of treatment failure. The routine use of therapeutic drug monitoring for voriconazole [9] would identify low concentrations and allow dose adjustment in such patients. However, the association of low initial trough voriconazole concentrations with increased mortality [8] implies this may not ensure a positive clinical outcome in all cases. The authors are not aware of any published studies that have investigated voriconazole metabolism in CYP2C19*17 homozygotes (CYP2C19*17/*17). It may be expected that these subjects would display further reduced voriconazole exposure when compared with homozygous extensive metabolizers, as is the case for omeprazole [1]. Furthermore, no studies have yet assessed the impact of the CYP2C19*17 allele on the pharmacokinetics of voriconazole at steady state. Considering the clinical consequences of low voriconazole concentrations, we recommend awaiting the results of larger, multiple dose studies including CYP2C19*17 homozygotes before discounting the clinical importance of the CYP2C19*17 allele for voriconazole therapy. There are no competing interests to declare." @default.
• W1946652904 created "2016-06-24" @default.
• W1946652904 creator A5015289452 @default.
• W1946652904 creator A5045823606 @default.
• W1946652904 date "2010-12-09" @default.
• W1946652904 modified "2023-10-16" @default.
• W1946652904 title "Clinical importance of the CYP2C19*17 variant allele for voriconazole" @default.
• W1946652904 cites W1900202826 @default.
• W1946652904 cites W1964720826 @default.
• W1946652904 cites W1992995027 @default.
• W1946652904 cites W2014557179 @default.
• W1946652904 cites W2048111050 @default.
• W1946652904 cites W2051816101 @default.
• W1946652904 cites W2063905878 @default.
• W1946652904 cites W2065343663 @default.
• W1946652904 cites W2123134253 @default.
• W1946652904 cites W2162857158 @default.
• W1946652904 cites W4237615604 @default.
• W1946652904 doi "https://doi.org/10.1111/j.1365-2125.2010.03801.x" @default.
• W1946652904 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3018036" @default.
• W1946652904 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21143511" @default.
• W1946652904 hasPublicationYear "2010" @default.
• W1946652904 type Work @default.
• W1946652904 sameAs 1946652904 @default.
• W1946652904 citedByCount "15" @default.
• W1946652904 countsByYear W19466529042012 @default.
• W1946652904 countsByYear W19466529042014 @default.
• W1946652904 countsByYear W19466529042015 @default.
• W1946652904 countsByYear W19466529042016 @default.
• W1946652904 countsByYear W19466529042020 @default.
• W1946652904 countsByYear W19466529042021 @default.
• W1946652904 crossrefType "journal-article" @default.
• W1946652904 hasAuthorship W1946652904A5015289452 @default.
• W1946652904 hasAuthorship W1946652904A5045823606 @default.
• W1946652904 hasBestOaLocation W19466529042 @default.
• W1946652904 hasConcept C104317684 @default.
• W1946652904 hasConcept C112705442 @default.
• W1946652904 hasConcept C126322002 @default.
• W1946652904 hasConcept C135763542 @default.
• W1946652904 hasConcept C140840227 @default.
• W1946652904 hasConcept C16005928 @default.
• W1946652904 hasConcept C170734499 @default.
• W1946652904 hasConcept C180754005 @default.
• W1946652904 hasConcept C2779548794 @default.
• W1946652904 hasConcept C2780690907 @default.
• W1946652904 hasConcept C29730261 @default.
• W1946652904 hasConcept C33664856 @default.
• W1946652904 hasConcept C3946865 @default.
• W1946652904 hasConcept C526171541 @default.
• W1946652904 hasConcept C54355233 @default.
• W1946652904 hasConcept C55775858 @default.
• W1946652904 hasConcept C62231903 @default.
• W1946652904 hasConcept C71924100 @default.
• W1946652904 hasConcept C86803240 @default.
• W1946652904 hasConcept C98274493 @default.
• W1946652904 hasConceptScore W1946652904C104317684 @default.
• W1946652904 hasConceptScore W1946652904C112705442 @default.
• W1946652904 hasConceptScore W1946652904C126322002 @default.
• W1946652904 hasConceptScore W1946652904C135763542 @default.
• W1946652904 hasConceptScore W1946652904C140840227 @default.
• W1946652904 hasConceptScore W1946652904C16005928 @default.
• W1946652904 hasConceptScore W1946652904C170734499 @default.
• W1946652904 hasConceptScore W1946652904C180754005 @default.
• W1946652904 hasConceptScore W1946652904C2779548794 @default.
• W1946652904 hasConceptScore W1946652904C2780690907 @default.
• W1946652904 hasConceptScore W1946652904C29730261 @default.
• W1946652904 hasConceptScore W1946652904C33664856 @default.
• W1946652904 hasConceptScore W1946652904C3946865 @default.
• W1946652904 hasConceptScore W1946652904C526171541 @default.
• W1946652904 hasConceptScore W1946652904C54355233 @default.
• W1946652904 hasConceptScore W1946652904C55775858 @default.
• W1946652904 hasConceptScore W1946652904C62231903 @default.
• W1946652904 hasConceptScore W1946652904C71924100 @default.
• W1946652904 hasConceptScore W1946652904C86803240 @default.
• W1946652904 hasConceptScore W1946652904C98274493 @default.
• W1946652904 hasIssue "1" @default.
• W1946652904 hasLocation W19466529041 @default.
• W1946652904 hasLocation W19466529042 @default.
• W1946652904 hasLocation W19466529043 @default.
• W1946652904 hasLocation W19466529044 @default.
• W1946652904 hasOpenAccess W1946652904 @default.
• W1946652904 hasPrimaryLocation W19466529041 @default.
• W1946652904 hasRelatedWork W1946652904 @default.
• W1946652904 hasRelatedWork W1987684861 @default.
• W1946652904 hasRelatedWork W2098899598 @default.
• W1946652904 hasRelatedWork W2235179640 @default.
• W1946652904 hasRelatedWork W2346498199 @default.
• W1946652904 hasRelatedWork W2463588639 @default.
• W1946652904 hasRelatedWork W2990706347 @default.
• W1946652904 hasRelatedWork W3025903047 @default.
• W1946652904 hasRelatedWork W3096347524 @default.
• W1946652904 hasRelatedWork W4210754005 @default.
• W1946652904 hasVolume "71" @default.
• W1946652904 isParatext "false" @default.
• W1946652904 isRetracted "false" @default.
• W1946652904 magId "1946652904" @default.
• W1946652904 workType "article" @default.